Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

BCL-2 inhibitor ICP-248

An orally bioavailable inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), with potential pro-apoptotic and antineoplastic activities. Upon oral administration, Bcl-2 inhibitor ICP-248 targets, binds to and inhibits the activity of Bcl-2. This restores caspase-mediated apoptosis in tumor cells. Bcl-2 is overexpressed in many cancers and plays an important role in the negative regulation of apoptosis. Its expression is associated with increased drug resistance and tumor cell survival.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:BCL2 inhibitor ICP-248
Code name:ICP 248
ICP-248
ICP248
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search